Banking

Ligand Pharmaceuticals Stock Shows Market Leadership With Jump To 82 RS Rating

Ligand Pharmaceuticals (LGND) stock saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 71 to 82.




X



When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

This unique rating measures technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock’s price action over the last 52 weeks matches up against that of all other stocks.

History shows that the market’s biggest winners tend to have an 80 or better RS Rating as they begin their biggest runs.


Looking For The Best Stocks To Buy And Watch? Start Here


Is Ligand Pharmaceuticals Stock A Buy?

After hitting a 52-week high of 219.75 on Feb. 10, Ligand Pharmaceuticals stock has pulled back into a long consolidation. It’s currently out of a proper buy range. Look for the stock to offer a new chance to get in like a three-weeks tight or pullback to the 50-day or 10-week line. Read “Looking For The Next Big Stock Market Winners? Start With These 3 Steps” for more tips. Also, check out “Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks.”

 

The biotech firm saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 58% to 63%. Revenue rose from 66% to 104%.

Ligand Pharmaceuticals stock earns the No. 8 rank among its peers in the Medical-Biomed/Biotech industry group. Biontech Se Ads (BNTX) and Alkermes (ALKS) are also among the group’s highest-rated stocks. For more industry news, check out “Biotech And Pharmaceutical Industry And Stock News.”

YOU MIGHT ALSO LIKE:

MarketSmith’s Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks

Most Related Links :
Business News Governmental News Finance News

Source link

Back to top button